HHS Rejects Bid to Broaden Access to Enzalutamide

Tony Hagen @oncobiz
Published: Wednesday, Jun 22, 2016
Francis Collins

Francis Collins

To the dismay of patient advocates, the Department of Health and Human Services (HHS) has turned down a request to override the patent for prostate cancer drug enzalutamide (Xtandi) so that it can be sold to a broader base of patients at a reduced price.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication